Exhibitor Spotlight | Vaccines, Veterinary Medicines, Reproductive Health and Biosecurity
Protecting herd health is no longer a matter of finding one product for one disease. Commercial pig production increasingly depends on an integrated system: prevention, diagnostics, vaccination, reproductive management, responsible use of medication, environmental control and day-to-day execution on the farm.
China's animal health sector is responding with a wider range of technologies. Vaccine platforms are becoming more specialized. Veterinary pharmaceutical manufacturers are building international quality standards and export capabilities. Reproductive programs are becoming easier to standardize, while microbial products, disinfection tools and data-assisted R&D are opening new paths for disease-risk management.
International visitors can explore these developments at the 15th Leman China Swine Conference and World Swine Industry Expo, to be held in Zhengzhou from October 22–24, 2026. The event's current plan includes 100,000 square meters of exhibition space, 800+ exhibitors and 150,000+ professional visitors.
For veterinarians, pig producers, pharmaceutical and vaccine companies, distributors, importers and technical-service teams, the expo offers more than a product showcase. It is an opportunity to compare technical approaches, review evidence with company specialists and identify potential supply, distribution and R&D partners in China.
Here are seven animal health exhibitors to add to your visit plan.
Pre-register as an International Visitor: https://s.31url.cn/rl9CH4Q9
1. Jinhe Biotechnology Co., Ltd.
From veterinary pharmaceuticals to vaccine platforms
Founded in 1990 and listed on the Shenzhen Stock Exchange under stock code 002688, Jinhe Biotechnology operates across veterinary pharmaceuticals, feed additives, animal vaccines, animal nutrition and related businesses. The company is a major producer of chlortetracycline products and has supplied international markets including North America and Southeast Asia.
Jinhe's animal vaccine business includes products developed by its subsidiary Hangzhou Uben Animal Vaccine Co., Ltd. One example is Youlanbao, an inactivated porcine reproductive and respiratory syndrome (PRRS) vaccine based on the CH-1a strain and formulated with the company's Uplus compound adjuvant.
Why visit: International buyers can discuss Jinhe's combination of active pharmaceutical ingredients, finished veterinary products and vaccines, as well as its quality management systems and experience serving export markets. Veterinarians can also ask how its PRRS vaccine is intended to fit within a broader herd-specific vaccination and monitoring program.
2. Ningbo Second Hormone Factory (NSHF)
Reproductive health and batch-production programs for sows
Established in 1988, NSHF specializes in veterinary reproductive hormones, covering raw materials, R&D, manufacturing, technical services and field application. The company applies experience from human pharmaceutical manufacturing to its veterinary formulations and works with universities and research institutes on reproductive technologies.
Its swine portfolio includes products based on buserelin, carbetocin and altrenogest, alongside a PMSG/hCG combination used in reproductive-management programs. NSHF also develops batch-production protocols for farms of different sizes, helping producers plan breeding, farrowing and pig flow more consistently.
Why visit: Sow-farm managers and veterinary teams can discuss synchronization, breeding management, batch farrowing and product-delivery formats. International visitors should also ask about registration status, approved indications, residue requirements and the availability of technical protocols for their target market.
3. Baigao Weisheng (Shanghai) Animal Pharmaceutical Co., Ltd.
A combined approach to respiratory health, nutrition and medication delivery
Baigao Weisheng is a Sino-foreign joint venture established in Shanghai in 2011. The company operates a veterinary GMP manufacturing facility and combines international production experience with technical services for Chinese farms.
Its “Qingjing Plan+” brings together several product categories. The portfolio includes Fra C12 Dry, based on alpha-monolaurin; Nutravit, a vitamin and nutritional premix; and Bestill, a 20% tilmicosin premix produced with a coated delivery system. These products are positioned for use within broader respiratory health, nutritional support and medication management programs.
Why visit: Producers and distributors can examine how nutrition, functional ingredients and veterinary medicines are combined into a program rather than sold as isolated products. For antimicrobial products, visitors should discuss approved labels, veterinary oversight, withdrawal periods and antimicrobial stewardship requirements in the destination market.
4. HVSEN Biotechnology Co., Ltd.
Integrated veterinary medicines and respiratory-health programs
Founded in 2002 and listed on the Shenzhen Stock Exchange under stock code 300871, HVSEN Biotechnology develops and manufactures veterinary active ingredients and finished products. The company reports commercial activity in around 30 countries and regions and maintains research platforms with universities and other scientific institutions.
Its swine portfolio includes Zhousoujing, a tylvalosin tartrate premix, and Taibisheng, a tildipirosin injection intended for veterinary management of susceptible bacterial respiratory infections. HVSEN also offers a multi-product program focused on supporting PRRS-positive herds through respiratory-health management, immune and nutritional support, and stress management.
Why visit: Veterinary and production teams can discuss how diagnostic information, vaccination, bacterial disease control and farm management should be coordinated in PRRS-positive herds. Buyers can also review HVSEN's API capabilities, finished-dose portfolio and technical support model.
5. Hebei Veyong Pharmaceutical Co., Ltd.
Antiparasitic and respiratory products with export-market experience
Hebei Veyong was established in 2002 and is part of Limin Group. The company develops and manufactures veterinary active pharmaceutical ingredients and finished products, with particular experience in antiparasitic and respiratory health categories.
Its portfolio includes active ingredients such as ivermectin, eprinomectin and tiamulin, supported by multiple finished-product lines. The company reports sales to more than 70 countries and regions and experience with international inspections, certification and export documentation.
Why visit: Importers and pharmaceutical partners can discuss API sourcing, formulation capabilities, analytical standards, regulatory dossiers and market-specific supply requirements. Producers can explore how parasite control and respiratory health programs may be designed around local epidemiology and veterinary guidance.
6. Pulike Biological Engineering, Inc.
Vaccine innovation for enteric and respiratory disease control
Pulike Biological Engineering is a an animal health company listed on the Shanghai Stock Exchange under stock code 603566. It develops veterinary biological products and pharmaceuticals and operates national-level innovation platforms while collaborating with major Chinese veterinary research institutes and universities.
For swine health, Pulike has introduced Puxie'an, an inactivated porcine epidemic diarrhea (PED) vaccine based on the XJ-DB2 strain. The product is positioned for maternal immunity programs and can be discussed alongside the company's live vaccine options as part of a farm-specific vaccination strategy.
Why visit: Veterinarians and integrators can review the strain rationale, antigen and adjuvant approach, recommended immunization program, field evidence and maternal-antibody strategy. International partners can also explore Pulike's broader vaccine platform, diagnostic capabilities and potential for technical cooperation.
7. Wuhan Keyuan Biological Development Co., Ltd.*
Microbial technologies, biosecurity and AI-assisted discovery
Founded in 2014, Wuhan Keyuan is a wholly owned subsidiary of Wuhan Keqian Biology Co., Ltd., a company listed on the Shanghai Stock Exchange STAR Market under stock code 688526. Keyuan focuses on microbial preparations and green feed additives for animal production.
The wider group has developed a microbial resource library containing thousands of strains and is exploring the use of artificial intelligence in areas such as compound screening and peptide design. Keyuan's featured swine products include Kezhilan, a microbial product developed for use in PRRS-related health programs, and the Kejiantai & Kexiaojing combination, positioned for farm biosecurity and African swine fever risk-management protocols.
Why visit:
This is a useful stop for visitors interested in non-traditional health technologies and AI-assisted R&D. Ask the technical team for product-registration status, full trial protocols, controls, sample sizes, statistical analysis, independent replication and instructions for safe integration with established veterinary and biosecurity programs.
What International Visitors Can Compare at the Expo
Together, these companies illustrate the breadth of China's animal health sector—from established pharmaceutical manufacturing to emerging microbial and digital research platforms.
During one visit, professionals can compare:
• live and inactivated vaccines, and program-based vaccine strategies;
• PRRS and PED management approaches;
• sow reproductive hormones and batch-production systems;
• veterinary APIs and finished-dose medicines;
• parasite-control and respiratory-health portfolios;
• microbial preparations and farm disinfection products; and
• export manufacturing, regulatory support and potential distribution partnerships.
Questions to Ask Every Animal Health Supplier
An exhibition conversation is most valuable when it goes beyond the product brochure. International buyers and technical teams may wish to ask:
1. Where is the product registered, and what indications are approved?
2. Is the evidence from laboratory challenge studies, controlled field trials or commercial-farm observations?
3. Were the studies independently reviewed or published, and can the full protocol be examined?
4. What GMP, batch-release, stability and pharmacovigilance systems are in place?
5. For vaccines, what are the strain match, cold-chain, and vaccination-program requirements?
6. For antimicrobials, what veterinary oversight, resistance-management and withdrawal-period rules apply?
7. Can the supplier support local registration, language, training, diagnostics and after-sales technical service?
These questions make it easier to distinguish an interesting product from a solution that can be responsibly introduced into a specific market or production system.
Meet China's Animal Health Sector in Zhengzhou
The 15th Leman China Swine Conference and World Swine Industry Expo will take place at the Central China International Convention and Exhibition Centre, Zhengzhou Airport Economy Zone, on October 22–24, 2026.
Professional visitors who complete pre-registration can attend the World Swine Industry Expo free of charge for all three exhibition days. The Leman China Pre-Conference Forum on October 22 is also complimentary under the current visitor offer. Registration fees apply to the full three-day conference program.
International participants can also request visa support documents after registration, while Chinese-English subtitle support and multilingual reception and business-matchmaking services are planned for the event.
Whether you are sourcing animal health products, evaluating vaccine and pharmaceutical technologies, seeking a Chinese distribution partner or building a more integrated herd-health program, Leman China 2026 offers a direct place to meet the people behind the technology.
Pre-register as an International Visitor: https://s.31url.cn/rl9CH4Q9
